Samsara Vision Announces Positive 6-Month Outcomes of SING IMT Surgery

Samsara Vision has reported promising intermediate-term visual and safety outcomes for the SING IMT (Smaller-Incision New-Generation Implantable Miniature Telescope). The 6-month post-surgery results demonstrate significant improvements in distance and near vision with a low impact on corneal endothelial cell density and manageable safety outcomes.

Key Findings

     • Visual Improvements:

               • At 6 months post-surgery, the following gains in best-corrected distance vision were achieved:

                     • 1-line improvement: 97.1% of operated eyes

                     • 2-line improvement: 68.6% of operated eyes

                     • 3-line improvement: 51.4% of operated eyes

               • The percentage of patients able to read at near distance increased from 28.6% at baseline to 97.1% at 6 months.

               • Distance vision improved by approximately 3 lines on average.

     • Safety and Corneal Health:

           • No clinically meaningful changes in intraocular pressure or anterior chamber depth were observed.

           • Mean corneal endothelial cell density change at 6 months: -280.7 (315.9) cells/mm² (-11.4%), indicating preservation of long-term corneal health.

Study Design

The retrospective study evaluated 35 patients (55 years or older) with late-stage age-related macular degeneration (AMD).

       • Post-surgery, patients participated in a structured rehabilitation program starting 6 weeks after implantation.

       • The program consisted of 8 sessions (90 minutes each) held every 2-3 weeks over 6 months to optimize visual outcomes.

Expert Insights

Prof. Toro, co-author of the study from University Hospital Federico II, Naples, Italy, emphasized the potential of the SING IMT:

“This 6-month review highlights the potential of SING IMT to restore meaningful vision to individuals blinded by AMD, while preserving long-term corneal health with its innovative design.”

Global Impact

The SING IMT is approved for use in CE Mark referenced countries, with over 400 patients across 19 countries already benefiting from this groundbreaking technology.

Conclusion

The 6-month outcomes of the SING IMT surgery highlight its ability to deliver significant visual improvement and maintain corneal health in patients with late-stage AMD. With its innovative design and structured rehabilitation program, the SING IMT represents a promising solution for restoring meaningful vision to those affected by AMD.